Delivery Order SPE2DB22D2206-SPE2DB25FEY13

Award Date 1/2/25
Potential Completion Date 1/3/25
Potential Value $4.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $1,462.45, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of BARHEMSYS 5 MG/2 ML VIAL 2ML, a pharmaceutical product, with a completion date of December 13, 2024. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $2,389.47 delivery order is for the supply of BARHEMSYS 5 MG/2 ML VIAL 2ML, a prescription medication. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and DLA, valued up to $999,999,999.00 through December 2025. The IDC enables DLA to efficiently procure a wide range of...
The federal contract award is for the delivery of BARHEMSYS 5 MG/2 ML VIAL 2ML pharmaceutical products to the Defense Logistics Agency (DLA) Troop Support Medical. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on December 17, 2024 with a ceiling value of $1,080.67. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued at $999,999,999 and running...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of BARHEMSYS 10 MG/4 ML VIAL 4ML, a specialty medication. The contract is a Delivery Order valued at $4,016.39 with a Firm Fixed Price pricing type. It was awarded on April 4, 2022, with an ultimate completion date of April 5, 2022. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant $999,999,999...
This federal contract award is for the delivery of BARHEMSYS 10 MG/4 ML VIAL 4ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $7,061.03 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on November 12, 2024. The contract has an ultimate completion date of November 13, 2024 and is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $4,680.41, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,406.00, is a delivery order under a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, worth up to $999,999,999.00 and running through November 2026. The contract covers the provision of a broad range of pharmaceutical products and medical supplies, including...
This federal contract award, valued at $4,263.84, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
The contract award is for the pharmaceutical product BARHEMSYS 5 MG/2 ML VIAL 2ML, with a ceiling value of $4,776.13. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, valued at $4,119.75, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp. The contract is a Delivery Order under an existing Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, which has a ceiling value of $999,999,999 and runs through November 2026. This IDC serves as a vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB25FEY13
    Delivery Order

This federal contract award, valued at $4,579.41, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of BARHEMSYS 10 MG/4 ML VIAL 4ML, a medical product, with a period of performance through January 3, 2025. This award is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition.

Generated 4/3/25, 10:54 AM